Market Report Source

Overview

Introduction
Following the lackluster 2004 launch of an oral suspension formulation of Santarus’ lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus’ future success is tied to the commercial potential for the recently launched Zegerid oral capsule formulation to drive near-term revenues.

Scope
Analyzes the commercial potential for Santarus’ Zegerid capsule, the first fast-acting capsule PPI to be approved the US FDA
Datamonitor interviewed eight gastroenterologists and primary care physicians familiar with the Zegerid oral capsule in the course of research

Highlights
Despite a very competitive prescription PPI landscape, we believe that Zegerid’s rapid absorption profile and data supporting its use in patients with nocturnal breakthrough GERD symptoms should provide Santarus and its marketing partner Otsuka with a relatively compelling marketing message for physicians.

As a result, we forecast US Zegerid revenues slightly ahead of Wall Street consensus.

Reasons to Purchase
Understand the commercial potential for Santarus’ Zegerid through in-depth analysis based on interviews with leading experts
Anticipate likely changes in the future market dynamics for GERD therapies following the likely success of Zegerid

Table of Contents

SUMMARY

Zegerid revenues expected to reach $229m by 2010

SANTARUS, INC.

Overview

Zegerid

GASTROESOPHAGEAL REFLUX DISEASE

Overview

Proton-pump inhibitors the standard of care for GERD patients

First immediate-release PPI approved in late 2004

Zegerid capsules launced in late March 2006

FACTORS AFFECTING THE POTENTIAL FOR SANTARUS’ ZEGERID

Physicians view immediate-release profile as intriguing GERD option

Data in nocturnal GERD patients could further spur Zegerid utilization

Third-party reimbursement tier key to future Zegerid growth

Additional OTC formulations could inhibit future growth in prescription PPI agents

Can Zegerid drive PRN dosing for mild-to-moderate GERD?

DATAMONITOR ZEGERID FORECAST

Novel marketing message and PRN potential should help Zegerid gain niche role

Product profile and PRN potential could make Zegerid an attractive OTC target

APPENDIX

Supplementary data

Datamonitor Healthcare

Disclosure information

Ask the analyst

List of Tables

Table 1: Estimated US Zegerid revenues 2006-2010

Table 2: Estimated US Zegerid revenues 2006-2010